Confo Therapeutics reports grant of two key patents for ConfoBodies™

- 02/12/2019

Ghent, Belgium: 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”.

The Steyaert patents – named after Prof Jan Steyaert (VIB-VUB), their first-named inventor and scientific founder of Confo Therapeutics – are a series of patents and patent applications that cover the composition-of-matter and various uses of ConfoBodies (single-domain antibodies capable of binding specific protein conformations) in structural biology and drug discovery. Confo Therapeutics holds the exclusive commercial rights to the Steyaert patent estate in the field of GPCR structure determination and drug discovery.

More info on Confo Therapeutics‘s website.